Cefminox Sodium | Meicelin | MT-141 | CAS#75498-96-3 | CAS#75481-73-1 | Penicillin Binding Protein Inhibitor

MedKoo Cat#: 329113 | Name: Cefminox Sodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefminox Sodium, also known as Meicelin and MT-141, is a penicillin binding protein inhibitor used to treat bacterial infection.

Chemical Structure

Cefminox Sodium

CAS#75498-96-3 (sodium)

Theoretical Analysis

MedKoo Cat#: 329113

Name: Cefminox Sodium

CAS#: 75498-96-3 (sodium)

Chemical Formula: C16H20N7NaO7S3

Exact Mass: 0.0000

Molecular Weight: 541.55

Elemental Analysis: C, 35.49; H, 3.72; N, 18.11; Na, 4.25; O, 20.68; S, 17.76

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 800.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

84305-41-9 (free acid) 75498-96-3 (sodium)

Synonym

Cefminox Sodium; MT-141; MT 141; MT141; Meicelin

IUPAC/Chemical Name

sodium (6R,7S)-7-(2-((2-amino-2-carboxyethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

SBIDXLKJYJVQOE-ZMUPEPPLSA-M

InChi Code

InChI=1S/C16H21N7O7S3.Na/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26;/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28);/q;+1/p-1/t8?,14-,16+;/m1./s1

SMILES Code

O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSCC(N)C(O)=O)=O)C1=O)[O-].[Na+]

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 75481-73-1(Cefminox) 75498-96-3(Cefminox Sodium)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 541.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wu S, Bi X, Lin Y, Yang L, Li M, Xie Y. Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report. Infect Agent Cancer. 2022 Jun 16;17(1):30. doi: 10.1186/s13027-022-00446-y. PMID: 35710562; PMCID: PMC9205056. 2: Garrido R, Novo A, Quintana S, Macía MA, Carrasco L, de Dios MJ, Romo JM, Sánchez M, Vargas M, Maciá M, Lapuente F, Mieza Y, Coronet P, Gimeno M, Carcas AJ, Frías J, Caballero Fernández V. Cefminox versus Cefoxitin in Hysterectomy Prophylaxis : Clinical Efficacy and Serum and Tissue Concentrations. Clin Drug Investig. 1997 Jun;13(6):317-25. doi: 10.2165/00044011-199713060-00004. PMID: 27519493. 3: Xia J, Yang L, Dong L, Niu M, Zhang S, Yang Z, Wumaier G, Li Y, Wei X, Gong Y, Zhu N, Li S. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134. doi: 10.3389/fphar.2018.00134. PMID: 29527168; PMCID: PMC5829529. 4: Corrales I, Aguilar L, Mato R, Frias J, Prieto J. Immunomodulatory effect of cefminox. J Antimicrob Chemother. 1994 Feb;33(2):372-4. doi: 10.1093/jac/33.2.372. PMID: 8182031. 5: Mashimo K. [New antimicrobial agent series XXIV: Cefminox]. Jpn J Antibiot. 1987 Sep;40(9):1549-65. Japanese. PMID: 3320395. 6: Kim JK, Kang H, Chae JS, Park YH, Choi YJ. Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus. FEMS Microbiol Lett. 2000 Jan 15;182(2):313-7. doi: 10.1111/j.1574-6968.2000.tb08914.x. PMID: 10620685. 7: Xu Y, Wang D, Tang L, Wang J. Separation and Characterization of Unknown Impurities and Isomers in Cefminox Sodium and Study of the Forming Mechanisms of Impurities by Liquid Chromatography Coupled with Ion Trap/Time-Of-Flight Mass Spectrometry. J Chromatogr Sci. 2019 Mar 1;57(3):204-212. doi: 10.1093/chromsci/bmy101. PMID: 30395207. 8: Aguilar L, Esteban C, Frias J, Pérez-Balcabao I, Carcas AJ, Dal-Ré R. Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. J Antimicrob Chemother. 1994 Jan;33(1):91-101. doi: 10.1093/jac/33.1.91. PMID: 8157579. 9: Sasagawa I, Yamaguchi O, Shiraiwa Y. Cefminox sodium penetration into prostatic tissue with and without inflammation. Int Urol Nephrol. 1991;23(6):569-72. doi: 10.1007/BF02549847. PMID: 1722784. 10: Hoellman DB, Spangler SK, Jacobs MR, Appelbaum PC. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501. doi: 10.1128/AAC.42.3.495. PMID: 9517922; PMCID: PMC105488. 11: Torres AJ, Valladares LD, Jover JM, Sánchez-Pernaute A, Frías J, Carcas AJ, Coronel P, Ródenas E, Pérez-Balcabao I, Fernández-Roblas R, Moreno M, Balibrea JL. Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial. Infection. 2000 Sep;28(5):318-22. doi: 10.1007/s150100070027. PMID: 11073141. 12: Watanabe T, Kazuno Y, Hirano F, Inouye S, Nishino T. Comparative in vitro and in vivo activity of cefminox (MT-141), cefotaxime and cefoperazone against gram-negative bacteria. Drugs Exp Clin Res. 1985;11(11):781-6. PMID: 3841789. 13: Watanabe K, Sawa K, Bunai M, Ueno K. Antibacterial activity of cefminox against anaerobes. J Antibiot (Tokyo). 1985 May;38(5):649-60. doi: 10.7164/antibiotics.38.649. PMID: 3874857. 14: Soriano F, Edwards R, Greenwood D. Comparative susceptibility of cefminox and cefoxitin to beta-lactamases of Bacteroides spp. J Antimicrob Chemother. 1991 Jul;28(1):55-60. doi: 10.1093/jac/28.1.55. PMID: 1769943. 15: Watanabe S, Omoto S. Pharmacology of cefminox, a new bactericidal cephamycin. Drugs Exp Clin Res. 1990;16(9):461-7. PMID: 2100248. 16: Sato T, Tasaki H, Ueda K, Kuroiwa T. [Clinical studies on cefminox in pediatric field]. Jpn J Antibiot. 1985 Mar;38(3):784-90. Japanese. PMID: 3897609. 17: Gastón de Iriarte E, Cárcamo Valor P, Diez-Enciso M, Prieto Prieto J, Pérez Balcabao I, Gimeno del Sol M, Coronel Granado P, Morán Soto MJ. Cefminox versus cefotaxima en el tratamiento de la infección urinaria complicada [Cefminox versus cefotaxime in the treatment of complicated urinary tract infection]. Actas Urol Esp. 1995 Sep;19(8):635-41. Spanish. PMID: 8669331. 18: Sasagawa I. [Study on the concentration of cefminox sodium in serum and prostatic tissue]. Hinyokika Kiyo. 1990 Jun;36(6):737-9. Japanese. PMID: 1700586. 19: Sun H, Wei L, Wu Y, Liu N. Simultaneous determination of aminomethylbenzoic acid, cefminox sodium and etamsylate in human urine by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 1;878(21):1899-903. doi: 10.1016/j.jchromb.2010.05.017. Epub 2010 May 24. PMID: 20570576. 20: Huelves L, Gracia M, Del Prado G, Rodríguez-Cerrato V, Martínez-Marín C, Ponte C, Soriano F, Coronel P, Gimeno M, Blanco J. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra- abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis. Int J Antimicrob Agents. 2006 Aug;28(2):151-3. doi: 10.1016/j.ijantimicag.2006.05.022. Epub 2006 Jul 3. PMID: 16815688.